about
Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medicationsSubclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohortsMortality associated with diabetes and cardiovascular disease in older women.Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons.Impact of carotid plaque screening on smoking cessation and other cardiovascular risk factors: a randomized controlled trial.Identifying familial hypercholesterolemia in acute coronary syndrome.Associations Between Cardiovascular Risk Factors, Inflammation, and Progression of Carotid Atherosclerosis Among Smokers.Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia - a proof-of-concept study.Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.[Resting heart rate: how to use it for cardiovascular prevention?].[New guidelines for screening and management of familial dyslipidemia].Low statin use in adults hospitalized with acute coronary syndrome.[Statins in primary prevention: how to share the decision?].Prognostic value of PCSK9 levels in patients with acute coronary syndromes.Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption.[Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?].[General internal medicine: review of year 2009 from the ambulatory perspective (2)].[Preventing weight gain in smoking cessation: there is no miracle solution].Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study.[Innovations in ambulatory care].[2012 literature findings in ambulatory internal medicine].Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort.Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score.Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate.Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.Carotid plaque screening as a motivational tool for healthy behavior.Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction.Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes.Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes.Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies.[Management of cardiovascular diseases in adults from 1999 to 2014: what has really changed?].Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European CohortSubclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular RiskStatins for Cardiovascular Prevention According to Different StrategiesGewisse Patienten profitieren von einem Selfmanagement der oralen Antikoagulation[2011 findings from literature on general internal ambulatory medicine]
P50
Q28541648-F305B5C0-AD44-440B-82E8-BAA5D4FA1D41Q34347696-6B6AAB0F-3E89-40DC-8DF2-7A48C78A265AQ36380616-28B3096D-0A27-43F9-940D-E56D65B637F3Q37312351-8CE28E41-F76C-4CF0-BCA7-B6F0039AF916Q38477034-0E099D11-E6D8-473D-BE89-E9249A5D8831Q38811718-8239A4E5-87A8-45AF-869A-C882D7559774Q38942185-C49958CA-EDB4-4784-A60C-16919E0078E7Q39517544-32EC7F59-AE0D-4839-BEDE-19F5EA7FF432Q40011452-07699B19-7E39-44B3-B875-C772F3F9C9B4Q40794248-0DE5F9EE-F836-42EA-AD1C-EED80386F855Q40794255-635CB00C-105D-4F8A-9EBE-31F5E68B59C0Q40904895-69C0BA97-AD1E-4D76-B222-D89EF223AD31Q40993712-5DBDCDF2-CFD3-486A-BAA8-55C25997110DQ41061002-F9CBDA17-8958-4629-B45A-8B8F3B1A75D1Q41613122-D8060679-F9FD-4B1C-9F9A-5BC9B936DC73Q42857344-E47BCE66-8206-471D-9327-46575158C461Q43107393-ADFB1BD3-D50C-4C92-9701-7E6115BC57CDQ43120161-17864C50-921A-424D-A634-2DD0D7072775Q43281433-7BEBE275-DF91-4BC0-89C2-21E537CB0CF4Q45829618-DA437A5B-16A5-4CB2-9895-893080A1CA66Q46097728-D878AB1C-3762-4997-8B67-8D4FEB5FBD16Q46126355-6E410555-B845-4122-80F7-94A262F36314Q47390481-8FFE7532-769A-4FC7-922C-D6850570E310Q47597427-F3AC3096-7533-4F0C-B3E6-D3561A033E88Q47960364-F25CDF0B-A2DC-4F6C-9113-96966F0A8EC2Q48014347-126588C5-8EC6-4F2B-9032-DE9B41FF381CQ48213904-85AC9875-30CD-4E2E-9114-312A221EC9CDQ48351891-9D0E3F78-3758-45CB-83E3-62480A8DE689Q50105196-F2E2E060-E4F3-4759-892E-2C42C4FD4CD3Q50190294-C06AE9DB-3E26-438F-984D-6038291D5BDAQ50593957-5DD48ADC-F682-457F-8FBE-2DD7833D116BQ50594217-4D81C0E0-C2E6-4FC7-AECB-9BCD0E6A11F6Q51840508-BA1F7FA2-0699-4786-B7F4-98127F69D321Q53220470-323FF4F8-B1A1-43D7-8ECA-42F371F3566EQ54940707-CC364584-656E-4E48-AC8C-B7D53DE5BC19Q57418655-2F3F4AE6-E5A2-45F4-9CB7-755F78440A90Q57418655-E7BEAEFA-B042-47B9-BEBD-88886A6A738DQ57530044-9F27BDFB-CAE2-4DFA-B6BB-6A29920EB6B8Q59660528-BE39DCD6-37EA-4B24-AE19-1B2D0AE1257DQ62651134-D2A1F2A2-1BCB-4AC0-9A5E-1CB71BB58BB9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Nanchen
@ast
David Nanchen
@en
David Nanchen
@es
David Nanchen
@nl
David Nanchen
@sl
type
label
David Nanchen
@ast
David Nanchen
@en
David Nanchen
@es
David Nanchen
@nl
David Nanchen
@sl
prefLabel
David Nanchen
@ast
David Nanchen
@en
David Nanchen
@es
David Nanchen
@nl
David Nanchen
@sl
P106
P21
P31
P496
0000-0002-2493-3505